肾脏病患者血清载脂蛋白A1、B、高密度脂蛋白胆固醇水平及临床意义  

Concentrations of apolipoprotein Al、apolipoprotein B and high-density lipoproteins in serum of renal disease patients:a pragmatic approach to assessing clinical significance

作　　者：洪景范 张文华[2] 隋洪[2] 

机构地区：[1]黑龙江省人民医院,哈尔滨150036 [2]黑龙江省临床检验中心

出　　处：《中华医学检验杂志》1996年第3期154-156,共3页

摘　　要：目的为探讨肾脏病患者继发动脉硬化性心血管合并症的危险性因素。方法采用免疫透射比浊法及酶法,测定了37例尚无合并症的肾脏病患者和86例健康人的血清载脂蛋白(apo)A1、apoB、高密度脂蛋白胆固醇(HDL-C)水平。结果对照组的 apoAl、apoB、apoA1/apoB、HDL-C 水平分别为:1.47±0.29g/L、0.92±0.20g/L、1.35±0.36、1.47±0.31mmol/L;患者组分别为:1.21±0.32g/L、1.32±0.24g/L、0.79±0.39、0.99±0.35mmol/L。两组间的各项结果差异均具有显著性意义(P<0.05)。结论肾脏病患者在出现动脉硬化性心血管合并症之前,体内已经具备了诱发合并症的生化基础,故治疗中应早期采取针对性预防措施。Objective To discuss the potential risk of atherosclerotie cardiac disease which may complicate any form of renal disease.Methods We measured apolipoprotein A1(apoA1),apolipopro- tein B(apoB)and high-density lipoproteins(HDL-C)with a behring nephelometor using monoclonal antisera and an enzyme end.The serum concentrations of risk factors in 37 renal disease patients with- out merging atherosclerotic cardiac disease and 86 controls in good health were measured.Results The apoA1,apoB,HDL-C and apoA1/apoB in the controls were 1.475±0.29g/L,0.92±0.20g/L.1.35± 0.36 and 1.47±0.31mmol/L respectively;and those in the patients were 1.21±0.32g/L,1.32±0.24 g/L,0.79±0.39 and 0.99±0.35 mmol/L respectively(P<0.05).Conclusions Severl studies have shoun that apoA1,apoB apoA1/apoB and HDL-C are significant predictors of atherosclerotic cardiac dis- ease.Unfortunately,these risk factors are present we suggest that in patients with renal disease.We suggest that a therosclerotic cardiac disease should be prevented early duing the clinical treatment of renal disease.

关 键 词：肾疾病 载脂蛋白 高密度脂蛋白 动脉粥硬化 

分 类 号：R692[医药卫生—泌尿科学] R541.4[医药卫生—外科学]